Previous winners

2021

Suvi Douglas

University of Helsinki, Helsinki

For a project investigating germline genetic predisposition to acute myeloid leukemia, acute lymphoblastic leukemia, and Waldenström macroglobulinemia

“My research fit the grant call so well. I study both leukemia and lymphoma and I am about one year from completing my PhD. This research is also important and the funding opportunities are limited. Now I have the opportunity to make germline predisposition to hematological malignancies more known. It feels great to get recognition that this is an important topic and there is a need for more knowledge on the genetic predisposition in hematological malignancies. This research gives the possibility to better understanding of the biology of normal hematopoiesis and how leukemia develops. This is also important for the patients that suffer from hematological malignancies and we can find new ways to help them.”

2021

Huan Cai

Karolinska Institutet, Stockholm

For a project exploring the therapeutic potential of recombinant laminin α4 in acute myeloid leukemia.

“I’m a young researcher within hematology so this grant was a great opportunity for me to dive deeper into my research and continue the work within a project exploring the therapeutic potential of recombinant laminin α4 in acute myeloid leukemia. The grant is a great support in terms of financing and motivation. The grant covers most of the cost related to the research project and that leaves me with a mental freedom to focus on the project instead of finances. At the same time knowing that The Nordic Incyte Grant committee see a great potential and interest in my project leaves me with a strong motivation to continue the work.”

2020

Stein-Erik Gullaksen

(University of Bergen, Norway)

For a project which will characterize the interaction of leukemic (CML) and healthy blood cells, and potentially will increase our understanding of the disease biology and therapeutic mechanisms, likely identifying biomarkers of early response to therapy through single cell immune profiling

“I applied for the Incyte Nordic Grant for Hematological Research, because the grant would give me a great opportunity to do the kind of research, which I have always wanted to do but never did, because of a lack of financial support. With the Grant, I have not only received financial support, but it has also given me the possibility to work within an exciting exploratory research field, which may lead to break outs that have never been seen before. I would recommend everyone with the interest of doing research to apply for The Incyte Nordic Grant for Hematological Research. It is a great opportunity for researchers, who aim for new, ground-breaking results, which patients in the future can benefit from.”

2019

Shady Awad

Helsinki

For a project investigating somatic mutations as drivers of treatment resistance and progression of chronic myeloid leukemia

2019

Rebecca Warwinge

Lund

For a project aiming at studying the correlation of CML stem cell heterogeneity to therapy response

2017-2018

Monika Dolinska

Stockholm

For a project aiming at uncovering the features of the CML leukemic cell niche and the role of different niche factors during CML development. Ultimately the project may lead to the identification of novel therapies targeting the leukemic niche for more effective antileukemic treatment.

2017-2018

Linda Arngården

Uppsala

For the development of a new method making it possible to detect and characterize single CML cells, potentially leading to the identification of predictive markers for CML disease remission and relapse after stop of TKI treatment.

2016

Helena Hohtari

Helsinki

For a novel approach to address the challenges of patients with Ph+ acute lymphoblastic leukemia (Ph+ ALL) who are in dire needs of effective therapy. This is to be done through identification of specific molecular/genetic markers predicting response to today’s treatment armamentarium and exploring sensitivity to novel agents. The ultimate goal is to develop curative treatment in Ph+ ALL, including patients not suitable for allogeneic stem cell transplantation.

2015

Jorrit Enserink

Oslo

For a study that has its focus on targeted therapy for Ph+ ALL where therapeutic breakthroughs have remained an unmet need. The study plan is highly interesting aiming at personalized medicine by finding novel molecularly targeted treatments through ex vivo drug profiling using a high throughput drug screen and further by in vivo drug efficacy testing in mouse models.

2015

Satu Mustjoki

Helsinki

For a novel approach to address the challenges of relapsing/progressing CML patients who are in dire needs of effective therapy. This is to be done through identification of driver mutations and involved pathways of pathogenesis and the identification of new targets and modes of action, all aiming at the development of curative combination therapy in CML